Strategy development for a manufacturing site following M&A in a pharmaceutical company
General Manager and Site Leader
Company:
Warner Chilcott Deutschland GmbH (part of Actavis)
Role:
General Manager of Warner Chilcott Deutschland GmbH and site leader of the Weiterstadt Site
Industry:
Pharmaceuticals
Revenue:
$13 Billion (Actavis), 100 Million € (Warner Chilcott Deutschland GmbH)
Employees:
Actavis: 10,000
Warner Chilcott: 350
Situation:
Integration following Acquisition by Actavis
Headquarters:
Ireland
Website:
www.actavis.com
(now part of Teva)
Responsibility(Revenue/Employees):
- Site Revenue approx. 100 Mio € with 350 Employees
Context:
- The local management team realized that the site needed a clear positioning and USP in order to be competitive in the new, large Actavis manufacturing network (with 25 sites running similar technologies)
Actions:
- SWOT Analysis
- Benchmarking with several sites of the Actavis network
- Alignment with global management on path going forward: maximising utilization of existing technologies through transfer of currently outsourced volumes
- Restructuring of the organisation (80 roles cut, approx >20% of the organization)
- Analysis of all transferable products completed, business cases developed and brought to decision to global management
Result:
- Utilization of existing equipment increased to maximum capacity (short term, until the generics business was sold to Teva)
- Additional volume manufactured without overhead growth